Achilles Capex To Depreciation from 2010 to 2024
| ACHL Stock | USD 1.01 0.03 2.88% |
Capex To Depreciation | First Reported 2010-12-31 | Previous Quarter 0.23339689 | Current Value 0.22 | Quarterly Volatility 3.63609315 |
Check Achilles Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Achilles Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 39.2 K, Depreciation And Amortization of 2.8 M or Selling General Administrative of 16.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.24. Achilles financial statements analysis is a perfect complement when working with Achilles Therapeutics Valuation or Volatility modules.
Achilles | Capex To Depreciation |
Latest Achilles Therapeutics' Capex To Depreciation Growth Pattern
Below is the plot of the Capex To Depreciation of Achilles Therapeutics PLC over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Achilles Therapeutics' Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Achilles Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capex To Depreciation | 10 Years Trend |
|
Capex To Depreciation |
| Timeline |
Achilles Capex To Depreciation Regression Statistics
| Arithmetic Mean | 2.45 | |
| Geometric Mean | 1.50 | |
| Coefficient Of Variation | 148.62 | |
| Mean Deviation | 1.81 | |
| Median | 1.49 | |
| Standard Deviation | 3.64 | |
| Sample Variance | 13.22 | |
| Range | 15.1259 | |
| R-Value | 0.15 | |
| Mean Square Error | 13.91 | |
| R-Squared | 0.02 | |
| Significance | 0.59 | |
| Slope | 0.12 | |
| Total Sum of Squares | 185.10 |
Achilles Capex To Depreciation History
About Achilles Therapeutics Financial Statements
Achilles Therapeutics investors utilize fundamental indicators, such as Capex To Depreciation, to predict how Achilles Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capex To Depreciation | 0.23 | 0.22 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Achilles Therapeutics Correlation against competitors. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.